Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Urogen Pharma Ltd - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
URGN
Nasdaq
8731
https://www.urogen.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Urogen Pharma Ltd
UroGen Pharma Ltd (URGN) Q1 2024 Earnings: Misses EPS Estimates, Revenue Slightly Above Expectations
- May 13th, 2024 1:32 pm
UroGen Pharma Announces Date for ENVISION Data, New Long-Term Jelmyto Durability Data, and Reports 2024 First Quarter Financial Results and Business Highlights
- May 13th, 2024 12:00 pm
Shareholders in UroGen Pharma (NASDAQ:URGN) have lost 67%, as stock drops 11% this past week
- May 12th, 2024 1:38 pm
UroGen Pharma to Participate at Upcoming Investor Conferences
- May 7th, 2024 12:00 pm
New Real-World Retrospective Analysis Presented at AUA 2024 Reports 86% Recurrence-Free Survival (RFS) at 24 Months with JELMYTO® Across All Studied Patient and Disease Characteristics in Cohort of Responders to Induction Therapy
- May 5th, 2024 4:20 pm
UroGen Announces Results from ATLAS Showing Robust UGN-102 Durability of Response in New and Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer at AUA 2024
- May 4th, 2024 7:20 pm
New Real-World Study on Retrograde Instillation of JELMYTO® for Treatment of Low-Grade Upper Tract Urothelial Cancer Reports Similar Complete Response Rate and Lower Stricture Rate Compared to OLYMPUS Pivotal Trial
- May 4th, 2024 3:50 pm
UroGen Pharma to Report 2024 First Quarter Financial Results on Monday, May 13, 2024
- May 3rd, 2024 12:00 pm
Pharming Group (PHAR) Surges 7.2%: Is This an Indication of Further Gains?
- Apr 22nd, 2024 9:29 am
UroGen Announces New Data Presentations at the American Urological Association 2024 Annual Meeting Highlighting Clinical Benefits of Our Portfolio for Urothelial Cancers
- Apr 17th, 2024 4:02 pm
UroGen Announces FDA Acceptance of Investigational New Drug Application for UGN-103, a Next Generation Mitomycin-Based Formulation for Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer
- Apr 15th, 2024 12:00 pm
UroGen Pharma Ltd.'s (NASDAQ:URGN) high institutional ownership speaks for itself as stock continues to impress, up 11% over last week
- Apr 14th, 2024 2:26 pm
UroGen Pharma Files Patent Infringement Action Against Teva Pharmaceuticals
- Apr 3rd, 2024 12:00 pm
UroGen Pharma Full Year 2023 Earnings: Revenues Beat Expectations, EPS In Line
- Mar 17th, 2024 12:55 pm
UroGen Pharma Ltd. (NASDAQ:URGN) Q4 2023 Earnings Call Transcript
- Mar 15th, 2024 2:30 pm
UroGen Pharma Ltd (URGN) Reports Solid JELMYTO Growth Amidst Financial Challenges
- Mar 14th, 2024 1:32 pm
Urogen Pharma (URGN) Reports Q4 Loss, Tops Revenue Estimates
- Mar 14th, 2024 1:10 pm
UroGen Pharma Delivers Double Digit JELMYTO® Growth and Prepares for the Next Phase of the Company with on Track Rolling Submission of UGN-102
- Mar 14th, 2024 12:00 pm
UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Mar 8th, 2024 1:00 pm
UroGen Pharma to Report Fourth Quarter and Full-Year 2023 Financial Results on Thursday, March 14, 2024
- Mar 4th, 2024 1:00 pm
Scroll